{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-060244","form_type":"8-K","ticker":"ALEC","cik":"0001653087","company_name":"Alector, Inc.","filed_at":"2023-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.946812+00:00","generated_at":"2026-06-08T15:47:25.722919+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Alector Q3 net loss $44.5M ($0.53/share); cash runway through 2025","bullets":["Collaboration revenue $9.1M, down from $14.9M YoY; net loss $44.5M vs $46.1M in Q3 2022.","Cash, equivalents & investments $588.9M; management expects sufficient runway through 2025.","Completed enrollment in pivotal INFRONT-3 Phase 3 trial of latozinemab for FTD-GRN with 103 symptomatic participants.","Completed enrollment in INVOKE-2 Phase 2 trial of AL002 for early Alzheimer's; data readout expected Q4 2024.","Reaffirmed FY 2023 guidance: collaboration revenue $90-100M, R&D $210-220M, G&A $60-65M."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-060244","json":"https://secwatch.observer/filing/0000950170-23-060244.json","markdown":"https://secwatch.observer/filing/0000950170-23-060244.md","text":"https://secwatch.observer/filing/0000950170-23-060244.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1653087/000095017023060244/0000950170-23-060244-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1653087/000095017023060244/alec-20231107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T15:47:25.722919+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a47553133d95ebb05cbf15eaede463bf69e4dcd4","claim":"Alector, Inc. reported financial results for the quarter ended September 30, 2023.","evidence_excerpt":"On November 7, 2023, Alector, Inc. (the “Company”) announced its financial results for the quarter ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1653087/000095017023060244/0000950170-23-060244-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}